Advances in Bioinformatics
Volume 2016 (2016), Article ID 9258578, 6 pages
http://dx.doi.org/10.1155/2016/9258578

Research Article

Molecular Docking and In Silico ADMET Study Reveals Acylguanidine 7a as a Potential Inhibitor of β-Secretase

Chaluveelaveedu Murleedharan Nisha,¹ Ashwini Kumar,¹ Prateek Nair,¹ Nityasha Gupta,¹ Chitrangda Silakari,¹ Timir Tripathi,² and Awanish Kumar¹

¹Department of Biotechnology, National Institute of Technology, Raipur, Chhattisgarh 492010, India
²Molecular and Structural Biophysics Laboratory, Department of Biochemistry, North Eastern Hill University, Shillong 793022, India

Received 20 November 2015; Revised 26 February 2016; Accepted 21 March 2016

Academic Editor: Huixiao Hong

Copyright © 2016 Chaluveelaveedu Murleedharan Nisha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Amyloidogenic pathway in Alzheimer’s disease (AD) involves breakdown of APP by β-secretase followed by γ-secretase and results in formation of amyloid beta plaque. β-secretase has been a promising target for developing novel anti-Alzheimer drugs. To test different molecules for this purpose, test ligands like acylguanidine 7a, rosiglitazone, pioglitazone, and tartaric acid were docked against our target protein β-secretase enzyme retrieved from Protein Data Bank, considering MK-8931 (phase III trial, Merck) as the positive control. Docking revealed that, with respect to their free binding energy, acylguanidine 7a has the lowest binding energy followed by MK-8931 and pioglitazone and binds significantly to β-secretase. In silico ADMET predictions revealed that except tartaric acid all other compounds had minimal toxic effects and had good absorption as well as solubility characteristics. These compounds may serve as potential lead compound for developing new anti-Alzheimer drug.

1. Introduction

Alzheimer’s disease (AD), the irreversible and progressive disease of the brain, is one of the most common causes of dementia in our society which gradually destroys our cognitive ability [1]. Alzheimer’s Association says it accounts for between 60% and 80% of all cases of dementia, occurring primarily in people above 60 years of age [2]. It is characterized by acceleration of amyloid β (Aβ) plaque accumulation around neurons and hyperphosphorylation of tau leading to the accumulation of neurofibrillary tangles (NFTs) within brain cells [3]. Furthermore, degradation of hyperphosphorylated tau by the proteasome is inhibited by the actions of Aβ. Amyloidogenic pathway is the result of a mutation that replaces the normal pathway in which α-secretase acts on the APP followed by γ-secretase forming harmless p-3 peptide but the amyloidogenic pathway involves breakdown of APP by β-secretase followed by γ-secretase and results in formation of amyloid beta plaque [4, 5].

The extracellular domain of β-amyloid precursor protein (APP) undergoes proteolytic cleavage by β-site APP cleaving enzyme (BACE 1 or β-secretase) followed by cleavage of the transmembrane domain of β-APP by γ-secretase. With all these cleavage sites and several peptides being produced, it is becoming more apparent that other APP-derived peptides beyond Aβ also may play critical roles in AD phenotype [6, 7]. Therefore, targeting BACE 1 enzyme could be useful in controlling the formation and appearance of the pathogenic amyloid β peptides. BACE 1 enzyme may hold a surprising central position. This is because cleavage of APP by BACE 1 not only generates the C-terminal fragment of APP that is the direct precursor of Aβ but also releases sAPPβ, which can interact with DR6 to effect neuronal damage. The γ-secretase cleavage of APP produces a fragment known as P83 after α-secretase pathway while it produces neurotoxic Aβ after β-secretase pathway [4]. Another important mechanism involving Aβ mediated neuronal inflammation and gradual cell death is their interaction with Receptors for Advanced Glycation End Products (RAGE) found on neurons and astrocytes [8], Figure 1.

Figure 1: The APP processing (in brief): APP: amyloid precursor protein; sAPP: soluble APP fraction; Aβ: amyloid beta; C-portion: C-terminal portion obtained from final cleavage.

Our study involves docking of β-secretase with four compounds, namely, acylguanidine 7a, tartaric acid, rosiglitazone, and pioglitazone, and comparison of these results with docking results of MK-8931 (as positive control) with β-secretase. Acylguanidine 7a, TZDs (thiazolidinediones), and tartaric acid were selected randomly based on a few previous studies [9–13]. MK-8931 is an anti-AD BACE 1 inhibitor candidate of Merck Inc. that has entered phase III clinical trials [14].

2. Materials and Method

2.1. Materials

Docking is a computational simulation approach of a candidate ligand binding to a receptor and predicts the preferred orientation of binding of one molecule to the second to form a stable complex. Docking is used to predict the affinity and activity of binding of the small molecule to their protein targets by using scoring functions. Hence, docking plays an important role in the rational design of drugs. The sensitivity of docking calculations regarding the geometry of the input ligand shows that even small changes in the ligand conformation can lead to large differences in the geometries and scores of the resulting docked poses.

Here, we worked with web-based online molecular docking program Docking Server. Drug-likeness was calculated with OSIRIS Property Explorer while the ADMET profiling was done with admetSAR program. The program was able to calculate the essential docking parameters with satisfactory results. It provided us with a detailed docking result against which we can determine the effectiveness of the test ligand.

2.2. Selection of Ligand

Analogs of acylguanidine 7a, rosiglitazone, pioglitazone, and tartaric acid were identified as potential β-secretase inhibitors from different literature reviews. Their structures were drawn afresh using the software ChemSketch (ACD/Labs, v12.01). Figures 2(a)–(e) show the structures of different ligands including the control compound MK-8931 from Merck.

Figure 2: Test ligands (a)–(e): acylguanidine 7a (a), pioglitazone (b), rosiglitazone (c), tartaric acid (d), and MK-8931 (control, e).

2.3. Selection of Receptor

The X-ray crystal coordinates of β-secretase (BACE 1) (PDB ID: 1SGZ) were retrieved from Protein Data Bank (http://www.rcsb.org/pdb/home/home.do). Since β-secretase has its crystal structure in a state that represents the pharmacological target for the development of new drugs to cure AD, it is selected for modeling studies. PDBsum (http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=index.html) server was used to determine the active sites of receptor and determine their interactions with compounds. BACE 1 is an aspartyl protease (Figure 2).

2.4. Molecular Docking

Docking Server (http://www.dockingserver.com/web) is a web-based, easy-to-use interface that handles all aspects of molecular docking from ligand and protein setup. It also provides full control on the setting of specific parameters of ligand and protein setup and docking calculations for more advanced users. It allows the user to carry out highly efficient and robust docking calculations by integrating a number of popular software programs used in in silico chemistry into one comprehensive web service.

2.5. Drug-Likeness Prediction

The OSIRIS Property Explorer uses chemical structures and calculates on-the-fly various drug-relevant properties whenever a structure is valid. Prediction results are valued and color coded. Properties analyzed are TPSA, calculation, calculation, molecular weight, fragment based drug-likeness, and drug score.

2.6. ADMET Prediction

ADMET properties of a compound deal with its absorption, distribution, metabolism, excretion, and toxicityin and through the human body. ADMET, which constitutes the pharmacokinetic profile of a drug molecule, is very essential in evaluating its pharmacodynamic activities. Today a lot of online tools and offline software programs are available which helps us in predicting this behaviour of the drug candidate. In this study, we have used the admetSAR prediction tool (http://lmmd.ecust.edu.cn:8000/).

3. Results and Discussion

We docked each of the four test ligands, namely, acylguanidine 7a, pioglitazone, rosiglitazone, and tartaric acid, with our target protein 1SGZ (β-secretase) separately by Docking Server. We found the following best results with each of the test ligands: Figures 3–7.

Figure 3: The target enzyme BACE 1 (memapsin 2, PDB ID: 1SGZ).

Figure 4: Docking of acylguanidine 7a with 1SGZ protein.

Figure 5: Docking of pioglitazone with 1SGZ protein.

Figure 6: Docking of rosiglitazone with 1SGZ protein.

Figure 7: Docking of tartaric acid with 1SGZ protein.

3.1. Binding Energy

Binding energy is the primary parameter which is generated as a result of molecular docking. It gives us the idea of strength and affinity of the interaction between the ligand and the receptor. The greater the binding energy is, the weaker the interaction is and vice versa. Thus during any docking study, we intend to look for the ligand which displays the least binding energy, thus the best affinity among the test molecules. Among the test candidates in this study, acylguanidine 7a displayed the lowest binding energy of −8.68 kcal/mol. The binding energy of the control MK-8931 was much higher than acylguanidine 7a, as found in our study; thus acylguanidine 7a displayed much better binding than the control molecule. The binding energies of the test ligands and the control have been depicted in Figure 8.

Figure 8: Binding energy values of the test ligands; MK-8931 is the study control.

3.2. Drug-Likeness Prediction Studies

A good drug candidate is absorbed in required time and well distributed throughout the system for its effective metabolism and action. Toxicity is another very important factor which often overshadows the ADME behaviour. Failure of drugs at clinical trial stage due to adverse effects generated because of their toxicity proves very expensive and detrimental in the drug development process. In silico drug-likeness prediction along with further ADME/Tox tools presents an array of opportunities which help in accelerating the discovery of new targets and ultimately lead to compounds with predicted biological activity. Table 1 depicts the drug-likeness properties of test compounds with least binding energies predicted using OSIRIS Property Explorer. The OSIRIS tool measures the value (logarithm of compound’s partition coefficient between -octanol and water) which is a well-established measure of the compound’s hydrophilicity. Higher value indicates lower hydrophilicity and, thus, poor absorption and permeation. A value indicates solubility; the lesser the value, the higher the solubility which would enhance the absorption. A lower molecular weight would again enhance the absorption rate and thus most of the drugs are tried to be kept at the lowest possible molecular weight [15]. TPSA or Topological Polar Surface Area indicates the surface belonging to polar atoms in the compound. An increased TPSA is associated with diminished membrane permeability and compounds with higher TPSA were better substrates for p-glycoprotein (responsible for drug efflux from cell). Thus comparing the compounds, lower TPSA was favorable for drug-like property. It was also predicted that a molecule with better CNS penetration should have lower TPSA value [16, 17]. Of all the toxicological features predicted like mutagenicity, tumorigenicity, irritability, and reproductive toxicity, only tartaric acid was found to be quite toxic to reproductive system and all the test ligands were free of other advert properties [15]. One of the test ligands of this study, acylguanidine 7a, was shown to comply best with these properties used to predict drug-likeness (Table 1).

Table 1: Drug-likeness prediction through OSIRIS Property Explorer.

S. number
Ligand

Solubility 

Molecular weight
TPSA
Drug score

1
Acylguanidine 7a
2.16
−4.02
318
86.4
0.69

2
Pioglitazone
3.08
−3.84
356
93.59
0.76

3
Rosiglitazone
2.10
−3.67
357
96.83
0.8

4
Tartaric acid
−2.71
0.32
150
115
0.57

3.3. ADMET Prediction

ADMET properties, as derived from admetSAR server, reveal that acylguanidine 7a and pioglitazone had better Human Intestinal Absorption (HIA) score than the control MK-8931. Greater HIA denotes that the compound could be better absorbed from the intestinal tract upon oral administration. The penetration through the Blood-Brain Barrier (BBB) came out to be best for acylguanidine and was significantly higher than the control molecule (0.9 versus 0.8, resp.). When it comes to predicting the efflux by P-glycoprotein (P-gp), acylguanidine comes out to be a substrate and noninhibitor of P-gp while pioglitazone came out as a nonsubstrate and noninhibitor of P-gp similar to our control molecule. Rosiglitazone was a substrate/noninhibitor while tartaric acid was a nonsubstrate/noninhibitor. In terms of metabolism, we found that acylguanidine was a nonsubstrate (but noninhibitor) of CYP450 microsomal enzyme while our control molecule was shown to be metabolized by CYP450 since it comes out to be a substrate and noninhibitor. A noninhibitor of CYP450 means that the molecule will not hamper the biotransformation of drugs metabolized by CYP450 enzyme. AMES toxicity test is employed to know whether a compound is mutagenic or not. Similar to the control MK-8931, all the test ligands displayed negative AMES toxicity test which means that the ligands are nonmutagenic. Carcinogenic profile also revealed that the ligands were noncarcinogenic similar to the control molecule. Acute oral toxicity was found to be highest for tartaric acid. All other test ligands and the control had low and almost similar oral toxicity. Important information obtained from admetSAR server was the computed LD50 dose in rat model. Comparing the LD50 doses, a compound with lower dose is more lethal than the compound having higher LD50. From our observation, we found that acylguanidine had almost the same LD50, compared to the control MK-8931 (2.58 versus 2.59, resp.). Tartaric acid had the lowest LD50 of 1.46 and was most toxic among the test ligands. Table 2 illustrates the various ADMET parameters obtained from admetSAR tool. Figure 9 depicts the comparative HIA, BBB, and LD50 values of the test ligands and the control.

Table 2: ADMET profile of the test ligands and the control.

Compound
HIA
BBB
CYP inhibition/substrate
AMES toxicity
Carcinogenicity
LD50 in rat

MK-8931 (control)
0.9823
0.8354
Substrate/noninhibitor
Nontoxic
Noncarcinogenic
2.5901

Acylguanidine 7a
0.9916
0.9069
Nonsubstrate/noninhibitor
Nontoxic
Noncarcinogenic
2.5881

Pioglitazone
0.9952
0.8753
Substrate/inhibitor
Nontoxic
Noncarcinogenic
2.0115

Rosiglitazone
0.9861
0.8994
Substrate/inhibitor
Nontoxic
Noncarcinogenic
2.4515

Tartaric acid
0.5320
0.8035
Nonsubstrate/noninhibitor
Nontoxic
Noncarcinogenic
1.4627

Figure 9: Comparative HIA, BBB, and LD50 of the test ligands and the control.

4. Conclusions

Our admetSAR study revealed that, comparing and analyzing all the parameters, acylguanidine 7a could be projected as a potent BACE 1 inhibitor. Its ADMET properties displayed much similarity with our control MK-8931 which is already in the advanced clinical trial. Tartaric acid was found to be least suitable because of the lowest LD50 value apart from other parameters. In conclusion, the compound acylguanidine 7a, followed by pioglitazone, could prove to be remarkable base drug candidates as they are potent, selective, orally bioavailable, and nontoxic β-secretase inhibitors. In the present study, we identified that the best result of all the dockings in Docking Server was obtained between 1-SGZ (target protein) and acylguanidine 7a followed by MK-8931 (control ligand) and then pioglitazone (thiazolidinedione class) with respect to their free binding energy, whereas OSIRIS Property Explorer has shown tartaric acid, of all four test ligands, to have the highest toxicity in terms of reproductive effects and hence it is unfavorable as a drug candidate, as verified above too. The present study represents only the in silico docking of four different test ligand compounds against our target β-secretase enzyme and their computational analysis. These ligands could be used as base structure and different structure modifications could possibly bring more potent molecules. We could not proceed further with the in vitro and in vivo testing due to lack of the required facilities, and thus this study needs further in vitro and in vivo animal studies for development and authentication of these probable potent inhibitors of β-secretase for the treatment of Alzheimer’s disease.

Competing Interests

The authors declare that there are no competing interests regarding the publication of this paper.

Authors’ Contributions

Chaluveelaveedu Murleedharan Nisha and Ashwini Kumar conducted the study and wrote the paper. Prateek Nair, Nityasha Gupta, and Chitrangda Silakari conducted the study. Timir Tripathi and Awanish Kumar designed and analyzed the paper and contributed to paper editing. All the authors read and approved the final paper. Chaluveelaveedu Murleedharan Nisha and Ashwini Kumar contributed equally to this study.

Acknowledgments

The authors are thankful to the Department of Biotechnology, National Institute of Technology Raipur (CG), India, for providing facility, space, and resources for this work. The study was partly supported by a research Grant from Science and Engineering Research Board, New Delhi, India (Grant no. SR/FT/LS/-206/2009) to Timir Tripathi.

References

National Institute of Aging, http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet

Alzheimer's Association, http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp

D. M. Niedowicz, P. T. Nelson, and M. Murphy, “Alzheimer's disease: pathological mechanisms and recent insights,” Current Neuropharmacology, vol. 9, pp. 674–684, 2011.

K. Sambamurti, N. H. Greig, and D. K. Lahiri, “Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease,” NeuroMolecular Medicine, vol. 1, no. 1, pp. 1–31, 2002.

R. H. Swerdlow, “Pathogenesis of Alzheimer's disease,” Clinical Interventions in Aging, vol. 2, no. 3, pp. 347–359, 2007.

K. W. Menting and J. A. H. R. Claassen, “β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease,” Frontiers in Aging Neuroscience, vol. 6, article 165, 2014.

R. Yan and R. Vassar, “Targeting the β secretase BACE1 for Alzheimer's disease therapy,” The Lancet Neurology, vol. 13, no. 3, pp. 319–329, 2014.

Y. K. Chuah, R. Basir, H. Talib, T. H. Tie, and N. Nordin, “Receptor for advanced glycation end products and its involvement in inflammatory diseases,” International Journal of Inflammation, vol. 2013, Article ID 403460, 15 pages, 2013.

D. C. Cole, E. S. Manas, J. R. Stock et al., “Acylguanidine as smallmolecule betasecretase inhibitors,” Journal of Medicinal Chemistry, vol. 49, no. 21, pp. 6158–6161, 2006.

Y. Zou, L. Li, W. Chen et al., “Virtual screening and structure-based discovery of indole acylguanidines as potent β-secretase (BACE1) inhibitors,” Molecules, vol. 18, no. 5, pp. 5706–5722, 2013.

L.-Y. Jiang, S.-S. Tang, X.-Y. Wang et al., “PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus,” CNS Neuroscience and Therapeutics, vol. 18, no. 8, pp. 659–666, 2012.

M. T. Heneka, M. Sastre, L. D. Ozimek et al., “Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV717I transgenic mice,” Brain, vol. 128, no. 6, pp. 1442–1453, 2005.

L. Gou-chao, N. Ai-hua, Z. Wu et al., “Synthesis of L-tartaric acid derivatives as novel inhibitors of BACE1,” Chinese Journal of Medicinal Chemistry, vol. 18, no. 6, pp. 406–413, 2008.

https://www.clinicaltrials.gov/ct/show/NCT01739348

http://www.organic-chemistry.org/prog/peo/

J. F. Blake, “Chemoinformatics-predicting the physicochemical properties of “drug-like” molecules,” Current Opinion in Biotechnology, vol. 11, no. 1, pp. 104–107, 2000.

L. K. Chico, L. J. Van Eldik, and D. M. Watterson, “Targeting protein kinases in central nervous system disorders,” Nature Reviews Drug Discovery, vol. 8, no. 11, pp. 892–909, 2009.